Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: A prospective randomized open-label trial

Diabetes, Obesity and Metabolism

Volumn 13, Issue 12, 2011, Pages 1149-1157

  Koivisto, V ^a   Cleall, S ^b   Pontiroli, A E ^c   Giugliano, D ^d  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Basal bolus therapy; HbA1c; Hypoglycaemia; Insulin glargine; Insulin lispro protamine suspension; Metabolic control; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; INSULIN LISPRO PROTAMINE SUSPENSION; UNCLASSIFIED DRUG;

AGED; ARTICLE; BACKACHE; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; VIRUS INFECTION; VITAL SIGN;

EID: 80055062558     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01484.x     Document Type: Article

References (15)

1. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes. A consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
2. Raccah D. Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus. Diabetes Obes Metab 2008; 10(Suppl. 2): 76-82.
3. Hompesch M, Ocheltree SM, Wondmagegnehu ET et al. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin 2009; 25: 2679-2687.
4. Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober SA. Randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with type 2 diabetes. Diabet Med 2010; 27: 181-188.
5. Esposito K, Ciotola M, Maiorino MI et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008; 149: 531-539.
6. Strojek K, Shi C, Carey MA, Jacober SJ. Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial. Diabetes Obes Metab 2010; 12: 916-922.
7. Mecklenburg RS. Insulin-pump therapy. In: Lebovitz H ed. Therapy for Diabetes Mellitus and Related Disorders, 3rd edn. ADA Clinical Education Series. Canada: American Diabetes Association, 1998; 204-210.
8. Skyler JS. Insulin treatment. In: Lebovitz H eds. Therapy for Diabetes Mellitus and Related Disorders, 3rd edn. ADA Clinical Education Series. Canada: American Diabetes Association, 1998; 186-203.
9. American Diabetes Association. Workgroup on Hypoglycemia Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249.
10. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review. Diabetes Res Clin Pract 2011; 92: 1-10.
11. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes: Meta-analysis of randomized controlled trials. Diabetes Care 2011; 34: 510-517.
12. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
13. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
14. ACCORD: Action to Control Cardiovascular Risk in Diabetes Study Group, Friedewald WT, Buse JB, Bigger RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
15. Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32: 187-192.